- PI Industries reported a net income of 4 billion rupees for the first quarter, which is an 11% decrease compared to the previous year.
- The net income missed analysts’ estimates, which were projected at 4.58 billion rupees.
- Company revenue for the quarter was 19 billion rupees, marking an 8.2% decrease from the previous year and falling short of the estimated 22.35 billion rupees.
- Agricultural Chemicals sales were reported at 18.3 billion rupees, showing a decline of 10% year-over-year.
- Pharmaceutical sales amounted to 723 million rupees, significantly higher than the previous year’s 253 million rupees but below the anticipated 825.1 million rupees.
- Total costs incurred by the company were 14.8 billion rupees, registering a reduction of 6.3% compared to the previous year.
- Investment analysts’ recommendations for PI Industries include 13 buy ratings, 7 hold ratings, and 7 sell ratings.
A look at Pi Industries Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
With a promising long-term outlook, Pi Industries is positioned to thrive based on its Smartkarma Smart Scores. The company scores high in Resilience and Growth, indicating strong durability in challenging times and potential for expansion. This bodes well for Pi Industries‘ ability to weather market fluctuations and capitalize on growth opportunities.
Furthermore, Pi Industries demonstrates solid momentum in its operations, suggesting a positive trajectory for the company. While the Value and Dividend scores are not as high, the company’s strengths in Growth and Resilience, coupled with its overall positive momentum, provide a foundation for long-term success in the industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
